Physician profile
Daniel E Hrad
NPI 1033166921
$7,126.68
in general payments reported to CMS, 2019-2025
30 companies · $2,383 in 2025
The $2,383 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $200 · 2021: $624 · 2022: $13.05 · 2023: $1,425 · 2024: $2,175 · 2025: $2,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,983.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $886.83 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $823.82 | 2021-2025 | Airsupra, Farxiga |
| Amgen INC. | $777.99 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $727.74 | 2021-2025 | |
| Novo Nordisk INC | $693.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $543.01 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $394.15 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.59 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $312.59 | 2021-2025 | Spravato |
| Viiv Healthcare Company | $304.40 | 2024-2025 | Apretude |
| Glaxosmithkline, LLC. | $237.03 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $179.26 | 2020-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Gilead Sciences, INC. | $134.19 | 2025 | |
| Amarin Pharma, INC. | $101.75 | 2019-2021 | |
| Exact Sciences Corporation | $93.33 | 2024-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $71.75 | 2023-2024 | Inspire |
| Abbott Laboratories | $70.67 | 2024-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $64.08 | 2023-2025 | Rexulti |
| Corium, LLC | $44.43 | 2023 | Azstarys, Adlarity |
| Sanofi Pasteur INC. | $38.28 | 2023-2025 | |
| Lundbeck LLC | $37.41 | 2023-2025 | Rexulti |
| Esperion Therapeutics, INC. | $35.63 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $28.72 | 2025 | Zoryve |
| Sumitomo Pharma America, INC. | $28.47 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $25.51 | 2025 | Symbravo |
| Eisai INC. | $23.04 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2025 | Eliquis |
| Cranial Technologies, INC | $14.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.05 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.